Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for […]
LaNova Medicines’ License Agreement with Turning Point Therapeutics
EQRx’s Collaboration with Insilico Medicine
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly […]
Insilico Medicine’s Drug Discovery Collaboration with Fosun Pharma
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the deal. Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and […]
Briggs & Stratton’s Acquisition of SimpliPhi Power
Wilson Sonsini Goodrich & Rosati advised SimpliPhi Power on the deal. Briggs & Stratton, a recognized global leader in providing power to get work done, has […]
Shell’s Acquisition of Inspire Energy Capital
Wilson Sonsini Goodrich & Rosati advised Inspire Energy Capital on the deal. Shell New Energies US LLC, a subsidiary of Royal Dutch Shell plc, announced that […]